Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57.7 CNY | +8.85% | +11.54% | +4.97% |
Apr. 25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
Apr. 25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
Sales 2024 * | 8.7B 1.2B | Sales 2025 * | 10.13B 1.4B | Capitalization | 42.86B 5.91B |
---|---|---|---|---|---|
Net income 2024 * | 2.12B 293M | Net income 2025 * | 2.61B 360M | EV / Sales 2024 * | 4.02 x |
Net cash position 2024 * | 7.91B 1.09B | Net cash position 2025 * | 10.85B 1.5B | EV / Sales 2025 * | 3.16 x |
P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
17.8
x | Employees | - |
Yield 2024 * |
1% | Yield 2025 * |
1.2% | Free-Float | 69.94% |
1 day | +0.78% | ||
1 week | +2.47% | ||
Current month | -0.26% | ||
1 month | +6.23% | ||
3 months | +8.49% | ||
6 months | -8.60% | ||
Current year | -3.57% |
Managers | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Hao Wu
PSD | President | 56 | 19-12-31 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Bing Hui Zhang
CHM | Chairman | 61 | 20-04-27 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 57.7 | +8.85% | 30 450 980 |
24-04-25 | 53.01 | +0.78% | 13,788,770 |
24-04-24 | 52.6 | -0.92% | 16,332,140 |
24-04-23 | 53.09 | +6.76% | 20,843,180 |
24-04-22 | 49.73 | +0.18% | 11,618,190 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.57% | 5.92B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.64% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- 300347 Stock